कंपनी का अवलोकन
IDEAYA Biosciences, Inc. operates within the healthcare sector specifically as a biotechnology firm dedicated to precision medicine oncology, focusing on discovering and developing targeted therapeutics for patient populations identified through molecular diagnostics in the United States. The company's primary asset is Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor designed for specific therapeutic indications. In terms of scale, IDEAYA holds a market capitalization of $2.72B and reports annual revenue of $218.71M, employing a workforce of 145 individuals. These valuation and revenue figures indicate that the company has achieved significant market traction for a biotechnology entity, positioning it as a substantial player despite the high-risk nature of the industry where revenue generation often precedes profitability in the early development phases of targeted therapies.
वित्तीय स्वास्थ्य
The company reported revenue of $218.71M over the trailing twelve months, yet recorded a net income of -$113,698,000 and an EBITDA of -$156,612,992, revealing a substantial gap between top-line growth and bottom-line profitability that points to a cost structure heavily weighted toward research, development, and clinical trial expenses. This negative free cash flow of -$52,472,624 suggests that the company is currently burning cash to fund its operational activities and drug development pipeline rather than generating immediate liquidity from its business operations. The gross margin stands at -43.9%, the operating margin is -869.5%, and the profit margin is -52.0%, indicating that the company is incurring significant losses across all layers of its financial performance, which is typical for biotechnology firms in the pre-commercialization or early commercialization stages where production costs and R&D overheads exceed sales revenue. Despite these losses, IDEAYA maintains a robust cash position of $639.39M against a total debt load of $27.91M, while holding a debt-to-equity ratio of 2.73, suggesting a leveraged balance sheet that relies heavily on equity financing rather than traditional debt obligations. The current ratio of 11.34 demonstrates an exceptionally high level of short-term liquidity, providing ample coverage for immediate obligations and reducing the risk of insolvency in the near term. Furthermore, the return on equity is -10.9% and the return on assets is -8.9%, metrics that reflect the company's current inability to generate positive returns on its capital base, which is a common characteristic for growth-stage biotech companies reinvesting all earnings into future product development.
मूल्यांकन आकलन
The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is calculated at -9.13, implying that the market is pricing in future earnings recovery or that current valuations are based on alternative metrics given the lack of positive historical earnings. The price-to-book ratio is 2.66, indicating that the market values IDEAYA at a premium of 166% over its book value, reflecting high investor expectations for the potential success of its drug portfolio and intellectual property. Additionally, the price-to-sales ratio stands at 12.45 and the EV/EBITDA is -13.48, suggesting that the company is valued primarily on its sales growth potential and asset base rather than current profitability, a standard approach for evaluating biotechnology firms with promising pipelines but unproven commercial viability. The stock has a 52-week high of $39.28 and a 52-week low of $13.45, meaning the current price sits at a level that reflects significant volatility within this trading range. The beta value is recorded as 0.02, which is exceptionally low and indicates that the stock's price movements are largely decoupled from the broader market fluctuations, exhibiting a level of stability unusual for small-cap biotechnology stocks.
Growth & Income
IDEAYA Biosciences demonstrated a revenue growth rate of 55.4% year-over-year, whereas earnings growth is listed as N/A due to the company's net losses, implying that top-line expansion is outpacing any potential for profitability in the current fiscal period. The company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash flow is being retained and reinvested into research, development, and clinical trials rather than distributed to shareholders. This reinvestment strategy is typical for companies in the biotechnology sector that prioritize long-term asset building and pipeline expansion over immediate income generation for investors. The overall growth and income profile of IDEAYA is characterized by rapid revenue expansion supported by a strong cash reserve, but currently devoid of income distribution, as the firm navigates the capital-intensive process of bringing targeted oncology therapeutics to market.